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Abstract
Background: The regulation of muscle stem cells in humans in response to muscle injury remains largely undefined.
Recently, interleukin-6 (IL-6) has been implicated in muscle stem cell (satellite cell)-mediated muscle hypertrophy in animals;
however, the role of IL-6 in the satellite cell (SC) response following muscle-lengthening contractions in humans has not
been studied.
Methodology/Principal Findings: Eight subjects (age 2261y ;7 9 68 kg) performed 300 maximal unilateral lengthening
contractions (3.14 rad.s
21) of the knee extensors. Blood and muscle samples were collected before and at 4, 24, 72, and
120 hours post intervention. IL-6, IL-6 receptor (IL-6Ra), cyclin D1, suppressor of cytokine signling-3 (SOCS3) mRNA were
measured using quantitative RT-PCR and serum IL-6 protein was measured using an ELISA kit. JAK2 and STAT3
phosphorylated and total protein was measured using western blotting techniques. Immunohistochemical analysis of
muscle cross-sections was performed for the quantification of SCs (Pax7
+ cells) as well as the expression of phosphorylated
STAT3, IL-6, IL-6Ra, and PCNA across all time-points. The SC response, as defined by an amplification of Pax7
+ cells, was
rapid, increasing by 24 h and peaking 72 h following the intervention. Muscle IL-6 mRNA increased following the
intervention, which correlated strongly (R
2=0.89, p,0.002) with an increase in serum IL-6 concentration. SC IL-6Ra protein
was expressed on the fiber, but was also localized to the SC, and IL-6
+ SC increased rapidly following muscle-lengthening
contractions and returned to basal levels by 72 h post-intervention, demonstrating an acute temporal expression of IL-6
with SC. Phosphorylated STAT3 was evident in SCs 4 h after lengthening contraction, and the downstream genes, cyclin D1
and SOCS3 were significantly elevated 24 hours after the intervention.
Conclusions/Significance: The increased expression of STAT3 responsive genes and expression of IL-6 within SCs
demonstrate that IL-6/STAT3 signaling occurred in SCs, correlating with an increase in SC proliferation, evidenced by
increased Pax7
+/PCNA
+ cell number in the early stages of the time-course. Collectively, these data illustrate that IL-6 is an
important signaling molecule associated with the SC response to acute muscle-lengthening contractions in humans.
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Introduction
Muscle specific stem cells, named satellite cells (SCs), are
necessary for muscle repair and regeneration and are known to
reside in skeletal muscle between the basal lamina and the
sarcolemma. Successful repair of muscle damage is dependent on
SCs to activate, proliferate and terminally differentiate [1,2]. The
contribution of new myonuclei to muscle fibers, from SCs, is
necessary to promote postnatal muscle growth and to prevent the
loss of functional capacity and increased morbidity and mortality
associated with muscle loss in advanced age and disease (bedrest,
cachexia, etc.) [3–5]. The paired box transcription factor, Pax7, is
necessary for the induction of the myogenic response following
muscle injury by promoting the transcription of the myogenic
regulatory factors (MRFs) as well as the maintenance of the SC
compartment through self-renewal [6–11]. It has been previously
shown that the SC pool is responsive to exercise-induced muscle
damage [12–14]; however, the regulation of this response remains
poorly understood. Many growth factors and cytokines such as,
hepatocyte growth factor (HGF), insulin-like growth factor-one
(IGF-1), IL-4 and leukemia inhibitory factor (LIF), among many
others, have been implicated in playing some role in regulating the
SC response [15–20]. However, the contribution of many of these
potential SC regulators to hypertrophy and muscle repair, in vivo,i s
not known.
IL-6 is a multifunctional cytokine primarily involved in immune
function [21]; however, the chronic systemic elevation of IL-6 in
disease states has been associated with promoting a catabolic state
PLoS ONE | www.plosone.org 1 June 2009 | Volume 4 | Issue 6 | e6027leading to muscle atrophy [22–24]. It has been previously
demonstrated that exercise can induce increases in muscle derived
IL-6 mRNA and plasma IL-6 concentrations following exercise
[25,26]. However, whether changes in IL-6 concentration can
influence human muscle SC function has yet to be examined.
Several recent studies provide key evidence that IL-6 signaling
may be important in myogenisis. It has been shown that skeletal
muscle possesses the IL-6 receptor (IL-6Ra) on the sarcolemma
and that the IL-6Ra is responsive to exercise [27]. It is well
established that IL-6 is produced by muscle in response to
inflammation and exercise [28–31] (for review see ref. [26]).
However, it was only recently that IL-6 was shown to play a
significant role in SC-mediated muscle hypertrophy [17]. IL-6
knock-out (IL-6
2/2) mice demonstrated a blunted hypertrophic
response and less SC-related myonuclear accretion compared to
wild-type mice following compensatory hypertrophy [17]. Fur-
thermore, SCs from IL-6
2/2 mice demonstrated an impaired
proliferative capacity, both in vivo and in vitro, which was shown to
be related to a lack of IL-6 mediated signal transducer and
activator of transcription-3 (STAT3) signaling [17]. Although IL-6
signaling has been shown to play an important role in the
hypertrophic response to overload in mice, the role of IL-6 in
muscle repair following injury in humans has not been elucidated.
Using a model of repeated muscle-lengthening contractions,
which we have previously shown to induce significant muscle
damage [32–34], we sought to induce a SC response and examine
the association of IL-6 with the SC response. We hypothesized that
IL-6 would play a key role in the human SC-mediated response to
contraction-induced muscle damage. Furthermore, based on the
work of Serrrano et al., [17] we hypothesized that SC-mediated
regulation by IL-6 would act through STAT3 signaling.
Results
The IL-6 Response to Muscle-Lengthening Contractions
(MLC)
In response to 300 maximal muscle-lengthening contractions,
serum IL-6 protein increased by approximately 2-fold (0.75 pg/
mL PRE to 2.25 pg/mL at T4, p,0.05) by T4 with respect to
baseline (PRE) levels. However, this response was transient,
returning to PRE levels by T120 (Fig. 1a). Interestingly, muscle IL-
6 gene expression demonstrated a parallel response. IL-6 mRNA
increased 4.5-fold from PRE at T4 (p=0.019) and returned to
baseline levels by T120 (Fig. 1b). Serum IL-6 was strongly
correlated to the increase in muscle IL-6 mRNA (r
2=0.89,
p=0.016) (Fig. 1c).
In order to test whether IL-6Ra gene expression was responsive
to our MLC protocol, we measured muscle IL-6Ra mRNA. IL-
6Ra gene expression was significantly increased in whole muscle at
T4 (p,0.001); however, these changes were transient as
expression levels returned to PRE values by T24 (Fig. 1d). In
addition, it has been recently shown that primary myoblasts
isolated from mice possess the IL-6Ra, however it remains
unknown whether human satellite cells possess the IL-6Ra [17].
Our observational immunofluorescent analysis revealed that
Pax7
+ cells co-localized with IL-6Ra, verifying that SCs in
humans possess the IL-6Ra (Fig. 1e).
Satellite Cell Response
The response of Pax7
+ cells to contraction-induced injury was
quantified across the post intervention time-course (see supple-
mental Fig. S1). The number of Pax7
+ cells (expressed as a
percentage of total myonuclei) increased 155% at T24
(3.3263.37% PRE to 8.4860.66% T24), peaking at T72 with a
184% increase from PRE (3.3263.37% PRE to 9.4560.83% T72;
p,0.005). The number of Pax7
+ cells began to decrease at T120,
but remained elevated as compared to PRE (p=0.007) (Fig. 2a, b).
To determine the percentage of Pax7
+ cells that were
proliferating, muscle cross-sections were co-stained with an
antibody against proliferating cell nuclear antigen (PCNA), a
marker for cells in early G1 and S phase of the cell cycle (see Fig.
S3). Pax7/PCNA co-staining revealed an increase in Pax7
+/
PCNA
+ cells as early as T4 (26% of Pax7
+ cells were PCNA
+),
peaking at T72 (58% of Pax7
+ cells were PCNA
+) and remaining
elevated at T120 (Fig. 2c, d). In order to test whether IL-6 was
present in SCs, we conducted triple immunofluorescent staining
for Pax7, IL-6, and DAPI.
Immunofluorescent triple staining of Pax7, IL-6, and DAPI,
revealed a substantial increase in the localization of IL-6 protein
within SCs (see Fig. S2). Figure 3a and 3b demonstrate the time-
course of IL-6 protein expression in Pax7
+ cells. IL-6
+ SCs
(expressed as a percentage of all Pax7
+ cells) increased from
,2.1661.47% of satellite cells PRE, to 58.9467.2% at T4 (Fig. 3c;
p,0.001) and peaked at 80.765.9% of satellite cells at T24
(p,0.001). By T72 the number of IL-6
+ SCs dropped 83% from
T24 (Fig. 3d) and returned to baseline levels by T120. The
increase in Pax7
+/IL-6
+ cells positively correlated with the
increase in Pax7
+/PCNA
+ cells observed from PRE to T24
(R
2=0.52, p,0.0001); however, after T24 there was no
correlation as SCs no longer expressed IL-6, whereas PCNA
+
SC number was still increasing.
JAK2/STAT3 signaling
It has been shown that IL-6-mediated muscle hypertrophy acts
via the Janus kinase/signal transducers and activators of
transcription (JAK/STAT3) signaling pathway [17]. To test if
IL-6 was associated with JAK/STAT3 signaling in response to our
MLC protocol, we analyzed JAK2 and STAT3 protein. Total and
phosphorylated JAK2 and STAT3 were unchanged across all
time-points following muscle damage (Fig. 4a, b). However,
immunofluorescent staining revealed phosphorylated STAT3 (p-
STAT3) co-localized with Pax7
+ cells only at T4 in all subjects
(Fig. 4c), with no detectable p-STAT3 at PRE, T24, T72 and
T120 indicating that STAT3 signaling was transiently active
within SCs at T4 (see Fig. S4).
In support of the observed p-STAT3 protein in SCs at T4, we
observed increases in both cyclin D1 and suppressor of cytokine
signaling-3 (SOCS3) mRNA in whole muscle, which are both
downstream genes regulated by IL-6-mediated JAK2/STAT3
signaling [35,36]. Cyclin D1 increased 4-fold at T4, peaked at T24
with a 6-fold increase in expression, and returned to baseline by
T72 as compared to PRE (p,0.05; Fig. 5a). SOCS3 mRNA
expression increased 6-fold at T24 (P,0.05) and showed a trend to
remain elevated at T72 (p=0.07) returning to baseline by T120
(Fig. 5b). Furthermore, SOCS3 mRNA was positively correlated
with the number of IL-6
+ SCs (R
2=0.50, p=0.02; Fig. 5c).
Discussion
The release of growth factors and cytokines in response to
muscle damage are an essential component of the muscle repair
process [12,16,31,37–39]. We have discovered that the pleiotropic
effects of IL-6 extend to the human satellite cell (SC) compartment
in response to eccentrically biased contraction-induced muscle
damage. Importantly, we have shown that human muscle SCs
express IL-6Ra in response to acute muscle injury suggesting that
IL-6 may play a role in regulating SCs. In addition, we have
shown that IL-6 is intimately associated with the SC response by a
IL-6 and Human Satellite Cells
PLoS ONE | www.plosone.org 2 June 2009 | Volume 4 | Issue 6 | e6027Figure 1. Circulating IL-6 and muscle IL-6 mRNA and IL-6 receptor response muscle lengthening contractions (MLC). (1a) Average
serum interleukin-6 (IL-6) concentration. Time 0 hr corresponds to pre-intervention values; all other time-points correspond to post-intervention time
(hr). (1b) Relative IL-6 mRNA expression, expressed as fold-change from 0 hr. (1c) Pearson correlation of serum IL-6 concentration versus muscle IL-6
mRNA (fold-change), correlation is representative of the individual data points and presented as mean values ($)6SD (error bars). (1d) Relative IL-6
receptor (IL-6Ra) mRNA expression, expressed as fold-change from 0 hr. (1e) Immunofluorescent image (406) of a muscle cross-section triple-stained
for Pax7 (red), IL-6Ra (green) and nuclei (DAPI=blue); IL-6Ra staining is apparent on the sarcolemma and satellite cell membrane. White arrow
denotes one of the Pax7
+ nuclei which co-localized with IL-6Ra (scale bar=100 mm). Values are reported as mean6S.E.M. Mean values represent the
mean for all 8 subjects per time-point (8 samples per time-point, 40 samples total). *p,0.05 vs. 0 hr.
doi:10.1371/journal.pone.0006027.g001
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PLoS ONE | www.plosone.org 3 June 2009 | Volume 4 | Issue 6 | e6027Figure 2. Muscle satellite cell response to muscle lengthening contractions (MLC). (2a) Triple-immunofluorescent staining of 7 mm muscle
cross-section for satellite cells (red=Pax7
+), laminin (green) and nuclei (DAPI=blue). Thin arrow denotes the Pax7
+ cell located beneath the basal
lamina in the satellite cell niche (scale bar=20 mm). (2b) Pax7
+ nuclei expressed as a percentage to total myonuclei following MLC. (2c) PCNA
+ cells
expressed as a percentage of all Pax7
+ satellite cells following MLC. (2d) Triple-immunofluorescent staining of 7 mm muscle cross-section for satellite
cells (green=Pax7
+), PCNA (red) and nuclei (DAPI=blue). Thin arrow denotes the PCNA
+/Pax7
+ cell, thick arrow denotes a Pax7
+ nuclei with no PCNA
staining (scale bar=20 mm). Values are reported as mean6S.E.M. Mean values represent the mean for all 8 subjects per time-point (8 samples per
time-point, 40 samples total). *p,0.05 vs. 0 hr; {p,0.05 vs. 4 hr; {p,0.05 vs. 120 hr.
doi:10.1371/journal.pone.0006027.g002
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PLoS ONE | www.plosone.org 4 June 2009 | Volume 4 | Issue 6 | e6027Figure 3. Satellite cell IL-6 protein expression following muscle lengthening contractions (MLC). (3a) Il-6
+ satellite cells expressed as a
percentage of all Pax7
+ satellite cells following MLC. (3b) Il-6
+ satellite cells expressed as a percentage of total myonuclei following MLC. Values are
reported as mean6S.E.M. Mean values represent the mean for all 8 subjects per time-point (8 samples per time-point, 40 samples total). *p,0.05 vs.
0 hr; {p,0.05 vs. 4 hr. (3c)IL-6/Pax7 co-localization following muscle lengthening contractions (MLC). Triple-immunofluorescent staining of 7 mm
muscle cross-sections for satellite cells (red=Pax7
+), IL-6 protein (green) and nuclei (DAPI=blue). The thin arrow denotes a Pax7
+/IL-6
+ cell and the
thick arrows denote Pax7
+ cells with no IL-6 staining (scale bar=10 mm). (3d) Representative image of 72 hr (T72) where white arrows denotes a
Pax7
+ cells with no IL-6 staining (scale bar=20 mm).
doi:10.1371/journal.pone.0006027.g003
IL-6 and Human Satellite Cells
PLoS ONE | www.plosone.org 5 June 2009 | Volume 4 | Issue 6 | e6027Figure 4. JAK2/STAT3 activity following muscle lengthening contractions (MLC). Representative western blot of phospho-Jak2 and Jak2
(4a) and phospho-Stat3 and Stat3 (4b). Graphs depict the ratio of phosphorylated to total protein. Data are presented as mean6SEM. Mean values
represent the mean for all 8 subjects per time-point (8 samples per time-point, 40 samples total). (4c) Triple-immunofluorescent staining of 7 mm
muscle cross-sections for satellite cells (green=Pax7
+), phosphorylated STAT3 protein (red) and nuclei (DAPI=blue). White arrows denotes Pax7
+/p-
STAT3
+ cell at 4 hr (T4), scale bar=10 mm. Note: No p-STAT3 staining found at T0, T24, T72 or T120 (not shown)
doi:10.1371/journal.pone.0006027.g004
IL-6 and Human Satellite Cells
PLoS ONE | www.plosone.org 6 June 2009 | Volume 4 | Issue 6 | e6027reporting a significant increase in IL-6 protein content within SCs
at T4 and T24, coinciding with an increase in Pax7
+ cell number
at T24 and an increase in the percentage of Pax7
+ cells actively
proliferating (evidenced by an increased percentage Pax7
+ cells
expressing PCNA). We observed p-STAT3 within the SCs at T4,
with the downstream genes cyclin D1 and SOCS3 increasing from
T4-T24, suggesting that the IL-6/STAT3 signaling pathway was
active within SCs early, during early proliferation, prior to the
expansion of the SC population. These findings establish evidence
that, in humans, IL-6 is fundamentally important to the
contribution of SCs to muscle repair and may, at least in part,
contribute to the proliferative component of the myogenic
program [17,29,40].
We observed a transient increase in IL-6 mRNA and IL-6
protein which agrees with previous findings where IL-6 peaked
early after intense resistance exercise in humans or compensatory
hypertrophy in animals [17,41]. It is well established that IL-6 can
be derived from skeletal muscle and released into circulation
following acute exercise [25,26,29]. Thus, it is not surprising that
our MLC protocol induced an increase in IL-6 mRNA and
circulating IL-6. In the present study, the increase in serum IL-6
was similar to previous studies which employed knee extensor or
short duration exercise [42–45]. However, since the MLC
protocol used in the present investigation only required approx-
imately 90 seconds of time under tension, coupled with the
relatively small muscle mass required by our protocol (quadriceps
group only), the contribution of circulating IL-6 from the muscle
was not as large as observed in studies involving strenuous whole-
body exercise (i.e. 2-fold vs. 128-fold increase) [46]. In the present
study a positive correlation between circulating IL-6 and muscle
IL-6 mRNA expression was observed (Fig. 1c), suggesting that
muscle-derived IL-6 protein may be released into circulation
accounting for the rise in plasma IL-6.
There are several mechanisms responsible for contraction-
induced muscle IL-6 production. For example, an increase in
intracellular calcium concentration in C2C12 myoblasts has been
shown to be a potent activator of IL-6 expression [29]. Although
calcium concentrations were not measured in this study, it is
possible that changes in intracellular calcium concentration as a
result of repeated muscle contractions may have contributed to the
Figure 5. The response of downstream genes of STAT3 signaling following muscle lengthening contractions (MLC). (5a) Relative
cyclin D1 mRNA expression (fold-change from 0 hr). (5b) Relative SOCS3 mRNA expression (fold-change from 0 hr). Values are reported as
mean6S.E.M. (5c) Pearson correlation of IL-6
+ satellite cells (number of cells) versus muscle SOCS3 mRNA (fold-change), correlation is representative
of the individual data points and presented as mean values ($)6SD (error bars). Mean values represent the mean for all 8 subjects per time-point (8
samples per time-point, 40 samples total). *p,0.05 vs. 0 hr; {p,0.05 vs. 4 hr.
doi:10.1371/journal.pone.0006027.g005
IL-6 and Human Satellite Cells
PLoS ONE | www.plosone.org 7 June 2009 | Volume 4 | Issue 6 | e6027increase in IL-6 expression [27,47]. In support of this notion it has
previously been reported that calcium channel blockers adminis-
tered prior to the same protocol used in the present investigation
resulted in reduced skeletal muscle damage, suggesting a role for
calcium-induced cellular damage [32]. Importantly, contraction-
induced calcineurin-NFAT, IL-1, AP-1, NFkB, and nitric oxide
signaling have been shown to induce IL-6 gene expression in
muscle [48,49] (for an extensive review see ref. [26]), suggesting a
potential role for calcium-induced IL-6 expression. Muscle
produced IL-6 can act in an autocrine fashion, binding to the
IL-6Ra on the sarcolemma, initiating the activation of the JAK/
STAT3 signaling pathway [17,26,50]. Although it has been
established that muscle can produce IL-6, SC-mediated IL-6
production has never been reported following injury in human
tissue.
Satellite cells contained virtually no IL-6 protein prior to the
MLC protocol (Fig. 3c). However, by T24, approximately 80% of
all Pax7
+ SCs were positive for IL-6. Interestingly, there was a
positive correlation between the increase in IL-6 and the increase
in PCNA co-localization with Pax7 early in the post-intervention
time-course. Furthermore, the number of SCs was not significantly
increased until T24, which suggests a potential role for IL-6 in
newly proliferating SCs. The number of SCs peaked at T72, at
which time IL-6
+ SCs had decreased close to baseline levels
(,10% IL-6
+ cells). Interestingly, we have previously reported that
Myogenin and MRF4 mRNA peak at the same time-point that SC
number peaks [39]. Since IL-6 was rapidly down-regulated prior
to this time it is worth suggesting that IL-6 may be intimately
involved in the proliferative process and the absence if IL-6 may
be necessary for differentiation to occur. Additionally, the timing
of increased IL-6 levels in the SCs in the current study is in
agreement with previous in vitro findings from animal studies [51]
that demonstrate a role for IL-6 in myoblast proliferation. In order
to investigate this notion, in vivo, we examined JAK2/STAT3
signaling in muscle.
Upon IL-6 binding to the IL-6Ra, JAK2 is phosphorylated and
initiates the phosphorylation of STAT3. STAT3 then forms a
dimer and translocates to the nucleus where it can act as a
transcription factor for several target genes [50]. JAK2/STAT3
signaling has been shown to induce the transcription of genes that
regulate cell cycle progression and proliferation such as cyclin D1
and c-myc [52–54]. In this study, there was no increase in whole
muscle p-JAK2 or p-STAT3 protein at the time-points in which
the muscle biopsies were obtained; however, the phosphorylation
of STAT3 is very rapid and transient and it is possible that any
increase in p-STAT3 detectable at the whole-muscle level
occurred before T4 [41,55]. Trenerry et al. (2007), observed an
increase in p-STAT3 protein in whole muscle 2 h after intense
resistance exercise that returned to baseline by 4 h. Alternatively,
it is possible that changes in protein phosphorylation events within
the SCs were too subtle to detect at the whole muscle level using
standard western blotting techniques. Indeed, using immunoflu-
orescent staining we showed p-STAT3 protein in the nuclei of SCs
at T4 but no other time-point. The co-localization of p-STAT3
with Pax7 may be due to the phosphorylation of STAT3 protein
within the SCs induced by the increase in IL-6 protein observed in
the SCs at T4. IL-6 may act in an autocrine manner, binding to
the IL-6Ra on the SC membrane, inducing the phosphorylation of
STAT3 via GP130/JAK2 activation within the SC [17,50,55].
The timing of the appearance of p-STAT3 in the SCs is in
agreement with observations made in rats demonstrating that SCs
expressed phosphorylated STAT3 3 h following injury [55]. The
authors of that study concluded that STAT3 signaling in SCs
following muscle injury was important for successful muscle
regeneration [55]. It is not surprising that p-STAT3 was found in
the nuclei of SCs following muscle injury, as SCs represent the
only resident mitotic cells within skeletal muscle and thus STAT3
signaling within these cells is inherently important for promoting
the activation of genes such as cyclin D1 which may help direct cell
cycle progression and proliferation of the SC pool.
Our data demonstrate the timing of cyclin D1 mRNA expression
not only mirrors the protein expression of IL-6 in the satellite cells,
but also coincides with the increasing proliferation of Pax7
+ cells.
Interestingly, IL-6
2/2 mice demonstrated a significantly blunted
number of p-STAT3
+ SCs accompanied by a significantly lower
level of cyclin D1 expression after 3 d of compensatory hypertrophy
as compared to wild-type animals [17]. In that study, the IL-6
2/2
animals had less muscle hypertrophy and less SC-mediated
myonuclear addition following compensatory overload, as a result
of impaired SC proliferation [17]. These findings illustrate the
importance of IL-6 mediated SC proliferation to the process of
skeletal muscle growth following overload or injury.
In addition, the rapid down-regulation of cyclin D1 at T72
illustrates the tight regulation of SC proliferation, and that rapid
down-regulation of cell-cycle genes may be necessary for the
induction of differentiation. In addition to inducing entry into the
cell cycle, cyclin D1 may also act in a negative feedback manner to
repress STAT3 activity by reducing nuclear p-STAT3 [56]. The
reduction of nuclear p-STAT3 may be necessary for the induction
of differentiation [57] and the timing of withdrawal of SC p-
STAT3 observed in the present study (i.e. no p-STAT3 evident at
T24 or later) supports this idea. Thus, the withdrawal of IL-6
mediated STAT3 signaling may be necessary for differentiation to
occur. This notion is strengthened by our observations that IL-6
protein is evident in 80% of satellite cells at T24 and less than 10%
of satellite cells at T72 corresponding to increases in MRF4 and
Myogenin (myogenic regulatory factors responsible for the initiation
of differentiation) observed at T72 previously [39]. This provides
further evidence that IL-6 signaling is withdrawn as differentiation
begins.
STAT3 phosphorylation is regulated by SOCS3 as part of a
negative feedback loop controlling the activation status of STAT3
proteins [58,59]. SOCS3 can bind phosphotyrosines on the JAK2
receptors, physically blocking STAT3 binding, as well as biding to
JAK2, directly blocking JAK kinase activity [50]. In addition,
SOCS3 can also recruit ubiquitin-transferases, facilitating the
ubiquitination of JAK2, targeting the JAK protein for proteosomal
degradation [26,50]. The expression of SOCS3 positively correlat-
ed with the increase in IL-6
+ SC, such that the subjects with the
highest number of IL-6
+ satellite cells had the highest expression of
SOCS3 mRNA (Fig. 5c). This correlation provides further support
that IL-6 is signaling through the STAT3 pathway. Moreover, the
timing of peak SOCS3 expression coincides with the peak in
satellite cell number and the down-regulation of cyclin D1
expression. Trenerry et al. (2007), reported similar findings
indicating that SOCS3 mRNA expression peaked 2 h after intense
resistance exercise, coinciding with the peak in c-myc mRNA and
p-STAT3 protein, after which p-STAT3 signaling was no longer
evident. The expression of SOCS3 and the absence of other
components of the IL-6/STAT3 signaling network beyond T24
illustrate the role of this network in promoting SC proliferation. In
addition, the transient nature of IL-6 expression may be of critical
importance in distinguishing IL-6 as a promoter of SC-mediated
muscle repair.
Classically, elevated IL-6 has been implicated in muscle wasting
diseases such as cachexia [23]. The pleiotropic roles of IL-6 appear
to be dependent on the stimuli, nature of the immune and local
tissue responses, and the temporal expression of IL-6 in inducing
IL-6 and Human Satellite Cells
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signaling in the context of muscle stem cell proliferation induced
by MLC. Our findings compliment recent data that implicate IL-6
as an essential regulator of SC-mediated hypertrophy in mice and
provide insight into the control of the SC response to muscle injury
and repair in humans. In summary, these findings suggest that IL-
6 may play a key role in SC proliferation in humans by inducing
genes such as cyclin D1 through the activation of JAK2/STAT3
signaling and that IL-6 is a factor mediating the repair response to
acute muscle damage.
Materials and Methods
Subjects
Eight healthy males (age 2261 y, height 18562 cm, weight
7968 kg) were recruited from the McMaster University commu-
nity. Subjects underwent a routine medical screening, completed a
health questionnaire, and were required to not have been involved
in a lower-body resistance exercise training program for at least 6
months prior to participating in the study. Subjects were told to
refrain from exercising throughout the time-course of the study.
All subjects were informed of the procedures and potential risks
associated with the study and gave their written informed consent
to participate. This study was approved by the Hamilton Health
Sciences Research Ethics Board and conformed to all declarations
on the use of human subjects as research participants.
Muscle Damage Protocol
We employed a protocol involving maximal isokinetic unilateral
muscle lengthening contractions of the quadriceps femoris performed
on a Biodex dynamometer (Biodex-System 3, Biodex Medical
Systems, Inc., USA) at 3.14 rad.s
21. Briefly, for each subject, one
leg was selected randomly to complete the protocol described
below. Movement at the shoulders, hips, and thigh were restrained
with straps in order to isolate the knee extensors during the
protocol.
Immediately prior to the intervention, subjects underwent a
brief familiarization trial involving 5 to 10 submaximal lengthen-
ing contractions of the leg under investigation. Subjects were
required to perform 30 sets of 10 maximal muscle lengthening
contractions with one minute rest between sets, for a total of 300
lengthening contractions. During each set, investigators provided
verbal encouragement in an attempt to elicit a maximal effort. It
has been well documented that our protocol induces a significant
level of skeletal muscle damage and substantial cellular disruption
evidenced by extensive z-band streaming, desmin disruption, a
significant increase in plasma creatine kinase (3.9-fold increase
48 h after exercise), a significant infiltration of macrophages and
neutrophils (4-fold and 14- fold increase 48 h after exercise
respectively) in addition to a significant myogenic regulatory factor
and satellite cell response (based on NCAM staining) [12,32–
34,39].
Muscle Biopsies
Five percutaneous needle biopsies were obtained from the mid-
portion of the vastus lateralis under local anesthetic (1% lidocaine)
using manual suction [60,61]. One muscle biopsy was obtained
from the non-working leg prior to the intervention. Baseline
measures were generated from the pre-intervention biopsy (PRE)
taken prior to beginning the damage protocol. Four biopsies were
obtained from the working leg at different time points following
the intervention. Muscle biopsies and blood draws were taken
concurrently, at 4 h (T4), 24 h (T24), 72 h (T72), and 120 h
(T120) post-intervention each from a new incision 3–5 cm
proximal to the last biopsy site. Approximately 150 mg of muscle
tissue was collected from each biopsy. Following collection of the
sample, the muscle was dissected free of adipose and connective
tissue, divided into separate pieces for RNA and protein analysis,
flash-frozen in liquid nitrogen, and stored at 280uC for later
analysis. Approximately 25 mg of each sample was mounted in
Optimum Cutting Temperature (OCT) compound and frozen in
isopentane cooled in liquid nitrogen. For each subject, 4, 24, 72
and 120 h biopsies were conducted at approximately the same
time of day (61 hour) in order to minimize variability between
subjects.
Immunofluorescence
7 mm sections were cryosectioned and stained with antibodies
against Pax7 (neat; DSHB, USA); IL-6 (500 ng/mL, MAB 2061,
R&D Systems, USA); p-STAT3 (p-STAT3 Y705 1:100, Cell
Signaling Technologies Inc., USA); IL-6Ra (1:50, MCA822,
Serotec, UK); PCNA (1:200, ab15497, Abcam Inc., USA); and
Laminin (1:1000, L8271, Sigma-Aldrich, Canada). Secondary
antibodies used were: Pax7 (AlexaFluor 488 or AlexaFluor 594,
1:500, Invitrogen, Molecular Probes Inc., USA); IL-6, IL-6Ra
(immunoglobulin biotinylated secondary antibody, 1:200, Dako
Canada, Inc.; followed by a streptavidin-FITC fluorochrome,
1:100, Biosource. USA); p-STAT3 (R-Phycoerythrin; 1:200;
Pierce, USA); PCNA (Texas Red, 1:500, Invitrogen, Molecular
Probes Inc., USA) and Laminin (AlexaFluor 488, 1:500, Invitro-
gen, Molecular Probes Inc., USA). For co-immunofluorescent
staining for Pax7 and IL-6, Pax7 and IL-6Ra, Pax7 and Laminin,
and Pax7 and p-STAT3 sections were fixed with 2% paraformal-
dehyde (PFA, Sigma, USA) for 10 min followed by several washes
in PBS. Sections were then covered for 30 min in a blocking
solution containing, 2% BSA, 5% FBS, 0.2% Triton-X 100, 0.1%
sodium azide; whereas for Pax7 and PCNA co-staining, fixing was
done with ice-cold acetone, and blocked with 10% goat serum
(GS) in 0.01% Triton-X 100 (Sigma, USA). Following blocking,
sections were incubated in the primary antibody at 4uC overnight.
After several washes, sections were then incubated in the
appropriate secondary antibodies. Sections were then re-fixed in
2% PFA (Sigma, USA) to prevent migration of the secondary
antibodies and re-blocked in 10% GS in 0.01% Triton-X 100
(Sigma, USA). The sections were then incubated in the second
primary antibody, followed by incubation in the appropriate
secondary antibody. Sections were then washed with PBS and
49,6-diamidino-2-phenylindole (DAPI) (Sigma, USA) for nuclear
staining. Staining was verified using the appropriate positive and
negative controls to ensure specificity of staining (see Fig. S5).
Stained slides were viewed with the Nikon Eclipse 90i Microscope
(Nikon Instruments, Inc., USA) and images were captured and
analyzed using the Nikon NIS Elements 3.0 software (Nikon
Instruments, Inc., USA).
Immunofluorescent Analysis
All immunostaining quantification and enumerations were
conducted on all subjects at all time points (n=8, 5 time-points,
40 biopsies total). For each time-point, images were taken at 406
to ensure a high resolution image to accurately determine nuclei
which were associated with myofibers and displayed co-localiza-
tion of immunolabeling. For each time-point measurement at least
15 different images per subject, per time-point were taken
corresponding to at least 1000 myonuclei.
Satellite cell enumeration. Satellite cell enumeration was
conducted with an anti-Pax7 antibody staining satellite cells and
DAPI staining all nuclei in the muscle cross sections. Only nuclei
which stained positive for Pax7 and DAPI were counted as satellite
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associated with myofibers were counted and interstitial nuclei
(based on their location relative to the basal lamina) were excluded
from enumeration. Data are presented with Pax7 positive (Pax7
+)
cells as a percentage of total myonuclei.
IL-6 positive satellite cells enumeration. Enumeration
was conducted using triple-immunolabeling with antibodies
against IL-6 and Pax7 and using DAPI to stain nuclei. Only
nuclei associated with myofibers were used to enumerate the
percentage of Pax7
+ cells which stained positive for IL-6 (Pax7
+/
IL-6
+). Data are presented with IL-6+ satellite cells (Pax7
+/IL-6
+)
as a percentage of total Pax7
+ cells as well as a percentage of total
myonuclei.
Proliferating cell nuclear antigen (PCNA) positive satellite
cells. Enumeration was conducted using triple-immunolabeling
with antibodies against PCNA and Pax7 and using DAPI to stain
nuclei. Only nuclei associated with myofibers were used to
enumerate the percentage of Pax7
+ cells which stained positive for
PCNA (Pax7
+/PCNA
+). Data are presented with PCNA
+ satellite
cells (Pax7
+/PCNA
+) as a percentage of total Pax7
+ cells.
Blood Measures
A resting blood sample was obtained from the antecubital vein
immediately prior to the intervention. Blood was also drawn at T4,
T24, T72 and T120. Approximately 5 mL of blood was collected
and separated into one heparinized and one non-heparinized
vacutainer tube at each time-point. Samples were separated into
50 mL aliquots and stored at 280uC for analysis at a later date.
Serum samples were thawed on ice and analyzed for IL-6 protein
using a commercially available Enzyme-Linked ImmunoSorbant
Assay (ELISA) kit according to manufactures instructions (R&D
Systems, Inc., USA). Samples were run in duplicate with an
average intra-assay CV of less than 2% with all subjects run on the
same plate.
RNA isolation
RNA was isolated from homogenized muscle samples using the
TRIzol/RNeasy method. Briefly, approximately 25 mg of each
muscle sample was homogenized in a total of 1.0 mL of TRIzol
Reagent (Invitrogen Corporation, Canada) using a rotary
homogenizer. Homogenized samples were incubated at room
temperature for 5 min followed by the addition of 0.2 mL of
chloroform then shaken vigorously for 15 s. After another 5 min
incubation at room temperature, samples were centrifuged at 12
000 g at 4uC for 10 min. The aqueous phase was then transferred
to a new tube and the volume was measured. 1 volume of 70%
ethanol was added to the aqueous phase and mixed. Multiple
700 mL aliquots were then transferred into a Qiagen RNeasy mini
spin column and RNA was purified by using the RNeasy mini kit
(Cat. # 74106), following the manufacturer’s instructions (Qiagen
Sciences, USA). The RNA was quantified and purity was assessed
using a spectrophotometer (NanoDrop 1000, Thermo Scientific,
USA). Random samples were also tested for RNA quality using
denaturing gel electrophoresis.
Reverse Transcription (RT)
Individual samples were reverse transcribed in 20 mL reactions
using a commercially available kit (Applied Biosystems High
Capacity cDNA Reverse Transcription Kit; Applied Biosystems,
USA) according to the manufacturer’s instructions. The cDNA
synthesis reaction was carried out using an Eppendorf Mastercycle
epgradient thermal cycler (Eppendorf, Canada).
Quantitative Real-Time Polymerase Chain-Reaction (qRT-
PCR)
Individual 25 mL reactions were prepared in 0.2 mL Stratagene
PCR tubes (Stratagene, USA) and run in duplicate for each time-
point. Primers were custom-made using published sequences
(Table 1) and were re-suspended in 1X TE buffer (10 mM Tris-
HCl, 0.11 mM EDTA) and stored at 220uC prior to use. In each
reaction tube, 1.0 mL of cDNA and 7.5 mL of ddH2O were added
to 16.5 mL of a master mix containing 12.5 mLo fR T
2 Real-Time
SYBR Green/Rox PCR master mix (SuperArray Bioscience
Corp., USA) along with 2 mL of the specific forward and reverse
primers. qRT-PCR reactions were carried out using a Stratagene
Mx3000P real-time PCR System (Stratagene, USA) using
Stratagene MxPro QPCR Software Version 3.00 (Stratagene,
USA). Fold changes in gene expression were calculated using the
delta-delta Ct method [62] normalized to the housekeeping gene
glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Table 1). Thus,
mRNA values were expressed as a fold change from PRE
(mean6SEM). GAPDH expression was not different from PRE at
any of the post-intervention time-points.
Western Blot Analysis
Muscle homogenates (7% wt/v) were prepared in ice-cold
homogenization buffer (20 mM Tris-HCl, 1 mM Na3VO4,
50 mM NaF, 40 mM b-glycerolphosphate, 20 mM NaPyrpho-
sphate, 0.5% Triton-X-100, 2 complete mini Roche protease
inhibitor tabs, pH 7.2). Equal amounts (50 mg) of protein, as
determined by Bradford Assay (Thermo Fisher Scientific, USA),
were loaded into lanes of a 7.5% gel, separated at 100 V for
90 min then transferred onto a polyvinyl difluoride (PVDF)
membrane (Millipore, Canada) for 60 min at 70 V. After blocking
for 1 h at 4uC in 5% bovine serum albumin (BSA, Santa Cruz
Biotechnology, USA) blots were probed with phospho-specific
primary antibody overnight at 4uC then relevant secondary
antibody. After phosphorylated protein detection by ECL (Super-
Signal West Dura; Thermo Fisher Scientific, USA) and Alpha
Table 1. qRT-PCR Primer Sequences.
Gene Name Forward Sequence Reverse Sequence Entrez Gene Accession Number
IL-6 59-GAAAGCAGCAAAGAGGCACT-39 59-AGCTCTGGCTTGTTCCTCAC-39 3569
IL-6Ra 59-GACAATGCCACTGTTCACTG-39 59GCTAACTGGCAGGAGAACTT-39 3570
Cyclin D1 59-CACGATTTCATTGAACACTTCC-39 59-TGAACTTCACATCTGTGGCAC-39 595
SOCS3 59-GACCAGCGCCACTTCTTCA-39 59-CTGGATGCGCAGGTTCTTG-39 9021
GAPDH 59-CCTCCTGCACCACCAACTGCTT-39 59-GAGGGGCCATCCACAGTCTTCT-39 2597
IL-6, interleukin-6; IL-6Ra, interleukin-6 receptor; SOCS3, suppressor of cytokine signaling 3; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.
doi:10.1371/journal.pone.0006027.t001
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membranes were stripped with Restore Western Blot Stripping
Buffer (Thermo Fisher Scientific, USA) for 20 min at room
temperature and detection of total-specific antibodies was
conducted. Bands were quantified using AlphaEase FC Software,
Version 5.0.2 (Alpha Innotech Corporation, USA). Levels of
phosphorylated protein were expressed relative to total.
The following primary antibodies were used; phospho-Stat3
(Tyr705) 1:1000, phospho-Jak2 (Tyr1007/1008) 1:500, Stat3
1:1000, and Jak2 (D2E12)1:500. All primary antibodies were
raised in rabbit and purchased from Cell Signaling Technology,
USA. A goat polyclonal to Rabbit IgG (HRP) secondary antibody
(1:50,000; Abcam Inc., USA) was used.
Statistical Analysis
Statistical analysis was performed using SigmaStat 3.1.0 analysis
software (Systat, SPSS Inc., USA). Serum IL-6 concentrations,
mRNA, protein, Pax7
+/IL-6
+, and Pax7
+/PCNA
+ enumeration
were analyzed using a 1-way repeated-measures analysis of
variance (ANOVA). Correlations were analyzed using the Pearson
Product Moment correlation. Statistical significance was accepted
at P,0.05. Significant interactions and main effects were analyzed
using the Tukey’s HSD post hoc test. All results are presented as
means6SEM.
Supporting Information
Figure S1 Muscle satellite (stem) cell response to muscle-
lengthening contractions (MLC): Triple-immunofluorescent stain-
ing of 7 mm muscle cross-section for satellite cells (red=Pax7+),
laminin (green) and nuclei (DAPI=blue). Thin arrows denote the
Pax7+ cells located beneath the basal lamina in the satellite cell
niche (206objective). (S1a): Pre-intervention; (S1b): 4 hours (T4);
(S1c): 24 hours (T24); (S1d): 72 hours (T72); (S1e): 120 hours
(T120) post-intervention.
Found at: doi:10.1371/journal.pone.0006027.s001 (7.26 MB TIF)
Figure S2 Satellite cell IL-6 protein expression following muscle
lengthening contractions (MLC): Triple-immunofluorescent stain-
ing of 7 mm muscle cross-sections for satellite cells (red=Pax7+),
IL-6 protein (green) and nuclei (DAPI=blue). (Figures S2a–c: 206
objective; Figures S2d–f: 406 objective). (S2a): Pre-intervention
(T0), note an absence of IL-6 co-localization (206); (S2b): Higher
magnification of T0 (406) arrows denote Pax7+ cells with no IL-6
positivity; (S2c): 4 hours (T4), note some IL-6 positivity (206) see
manuscript for higher magnification image of T4; (S2d): 24 hours
(T24), note increased IL-6 expression and Pax7/IL-6 co-
localization (206); (S2e): Higher magnification of T24 (406)
showing satellite cells staining positive for IL-6. (S2f): 120 hours
(T120) post-intervention (406), note an absence of IL-6 co-
localization. Note for T72 see manuscript.
Found at: doi:10.1371/journal.pone.0006027.s002 (9.94 MB TIF)
Figure S3 Satellite cell co-localization with proliferating cell
nuclear antigen (PCNA) following muscle lengthening contractions
(MLC): Triple-immunofluorescent staining of 7 mm muscle cross-
section for satellite cells (green=Pax7+), PCNA (red) and nuclei
(DAPI=blue). (S3a): Pre-intervention (T0), note absence of
PCNA; (S3b): 4 hours (T4); (S3c): 24 hours (T24); (S3d): 72 hours
(T72); (S3e): 120 hours (T120) post-intervention. All images
acquired with 406objective.
Found at: doi:10.1371/journal.pone.0006027.s003 (9.12 MB TIF)
Figure S4 Satellite cell co-localization with phosphorylated
STAT3 protein following muscle lengthening contractions
(MLC): Triple-immunofluorescent staining of 7 mm muscle cross-
sections for satellite cells (green=Pax7+), phosphorylated STAT3
protein (red) and nuclei (DAPI=blue). (S4a): Pre-intervention note
absence of satellite cell associated p-STAT3; (S4b): 4 hours (T4);
(S4c): 24 hours (T24), note absence of satellite cell associated p-
STAT3. Images acquired with 406objective.
Found at: doi:10.1371/journal.pone.0006027.s004 (5.17 MB TIF)
Figure S5 Control Images: (S5a): Immunofluorescent (IF) stain of
7 mm muscle cross-sections for IL-6Ra (green - streptavidin-FITC),
nuclei (DAPI) and the secondary antibody used for Pax7 (secondary
only - Alexa 594) acquired using the 206objective. Arrows denote
nuclei that co-localize with IL-6Ra and do not show any non-
specific secondary binding of the Alexa 594, or any Alexa 594
interaction with the IL-6Ra antibody. (S5b): Immunofluorescent
(IF) stain of 7 mm muscle cross-sections for Pax7 (red - Alexa 594),
nuclei(DAPI)and the secondaryantibodyused forIL-6(secondary-
tertiary only: immunoglobulin biotinylated secondary antibody +
streptavidin-FITC) acquired using the 206 objective. Arrows
denote nuclei that co-localize with Pax7 and do not show any
non-specific secondary binding of the secondary antibodies (FITC),
or any FITC interaction with the Pax7 antibody. (S5c): Immuno-
fluorescent (IF) stain of 7 mm muscle cross-sections for IL-6 (green -
streptavidin FITC), nuclei (DAPI) and the secondary antibody used
for Pax7 (secondary only - Alexa 594) acquired using the 206
objective. Arrows denote nuclei that co-localize with IL-6 and do
not show any non-specific secondary binding of the Alexa 594, or
any Alexa 594 interaction with the IL-6 antibody. (S5d):
Immunofluorescent (IF) stain of 7 mm muscle cross-sections for
PCNA (red- Texas Red), nuclei (DAPI) and the secondary antibody
used for Pax7 (secondary only - Alexa 488) acquired using the 206
objective. Arrows denote nuclei that co-localize with PCNA and do
not show any non-specific secondary binding of the Alexa 488, or
any Alexa 488 interaction with the PCNA antibody. (S5e):
Immunofluorescent (IF) stain of 7 mm muscle cross-sections for
Pax7 (green - Alexa 488), nuclei (DAPI) and the secondary antibody
used forPCNA (secondaryonly:TexasRed) acquired usingthe206
objective. Arrows denote nuclei that co-localize with Pax7 and do
not show any non-specific secondary binding of the secondary
antibody (Texas Red), or any Texas Red interaction with the Pax7
antibody. (S5f): Immunofluorescent (IF) stain of 7 mm muscle cross-
sections for phosphorylated STAT3 (p-STAT3) (red - Texas Red),
nuclei (DAPI) and the secondary antibody used for Pax7 (secondary
only - Alexa 488) acquired using the 206objective. Arrows denote
nuclei that co-localize with p-STAT3 and do not show any non-
specific secondary binding of the Alexa 488, or any Alexa 488
interaction with the PCNA antibody.
Found at: doi:10.1371/journal.pone.0006027.s005 (9.86 MB TIF)
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